A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice

Inclusion Criteria: * Participant lives in Canada. * Participant is experiencing VMS associated with menopause. * Participant is newly prescribed fezolinetant as part of routine clinical care but has not yet initiated the first dose. The decision to prescribe fezolinetant must be made prior to and independent of study participation. * Participant has acceptable hepatic function test results within the past 3 months prior to taking the first dose as described in the fezolinetant label. * Participant is a fluent speaker of English or French. * Participant is able to use digital devices and has access to an internet-capable device such as a mobile device or computer. Exclusion Criteria: * A participant will be excluded if they have contraindications as described in the fezolinetant label. * A participant will be excluded if they were previously treated with fezolinetant by a physician. * A participant will be excluded if they have been clinically diagnosed with a sleep disorder (e.g., insomnia, narcolepsy) and/or is taking medication to improve a sleep disorder not associated with VMS (i.e., a participant with sleep disturbance associated with VMS is eligible). * A participant will be excluded if they are currently participating in an interventional study or previously participated in another interventional study within 6 months of the first dose of fezolinetant.